Low-dose chemotherapy and less radiation for childhood Hodgkin lymphoma
Part of Ear, nose & throat clinical trials.
This trial studies a treatment plan for children with classical Hodgkin lymphoma that uses lower total doses of chemotherapy and reduced radiation. The goal is to help control the lymphoma while lowering long-term side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has been diagnosed with classical Hodgkin lymphoma (not the nodular, lymphocyte-predominant type).
- Kidney, liver, lung, and overall body chemistry tests are within normal ranges.
- If your child has certain immune problems, they should not be present before diagnosis.
- Your child (or guardian) can provide informed consent to join the study.
- It must be safe for your child to receive the study treatment based on pregnancy/breastfeeding and birth-control rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at a treatment approach for children and adolescents with classical Hodgkin lymphoma. It may help by testing how well the treatment controls the cancer and is tolerable in young patients.
This trial tests a combination of the immunotherapy drug sintilimab with chemotherapy (AVD) for children and teens with newly diagnosed low- or intermediate-risk Hodgkin lymphoma. The goal is to see if adding sintilimab can improve outcomes while reducing side effects.
This trial tests whether a lower dose of radiation, guided by PET scans, is safe and effective for people with early-stage but unfavorable Hodgkin lymphoma. It aims to reduce side effects while keeping the treatment strong.
This trial tests if proton beam radiation can effectively treat Hodgkin lymphoma while reducing side effects. It is for people with early-stage disease who have already completed chemotherapy and need radiation.
This Phase 2 study tests whether you can treat early-stage Hodgkin lymphoma with chemotherapy while avoiding radiation. It may help reduce radiation-related side effects if the treatment controls the cancer effectively.
This study tests a combination of a newer immunotherapy drug (nivolumab) with standard chemotherapy (AVD) in children, teens, and young adults with newly diagnosed, early-stage Hodgkin lymphoma—a blood cancer affecting lymph nodes. The goal is to see if adding immunotherapy improves outcomes while being tolerable for this age group.
Hear when a new Pediatric Hodgkin's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.